A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent
for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV)
chamber and to improve the delineation of the LV endocardial border. The primary objective of
this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.